Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs
Bullboard Posts
User Avatar Image
(6)
•••
Comment by BearDownAZon Jun 09, 2016 11:02am
206 Views
Post# 24950519

RE:RE:today's presentation and inauspicious trading

RE:RE:today's presentation and inauspicious tradingCraighenry wrote "Why wasn't RH there?" at ASCO.

Most likely because ASCO is more geared towards clinical oncology and BiOasis doesn't have results yet.

When I emailed RH yesterday to ask him to post the Q2 BIO 2016 slides, he also responded

"...(T)he company is very focused on working with License partners and companies that have entered into License Research agreements. However, that data remains confidential.  We are working on our LSD program with Scarpa and are in the midst of a dosing study, but that data is not out yet.  As for our oncology program we are in the process of preparing for a phase zero study, but the timing for that is predicated on material prep and patient availability."

So based on this, sounds like 1) BIO 2016 was the better venue for continuing to network and bring in new licensing partners; 2) LSD dosing study with Scarpa is still ongoiong; and 3) start of some human work is imminent. According to Wikipedia, the goals of Phase 0 studies are "Pharmacodynamics and Pharmacokinetics particularly oral bioavailability and half-life of the drug." RH said that IND filing is not necessary for Phase 0.

BearDownAZ
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities